Immunologic and toxicologic study of disaccharide tripeptide glycerol dipalmitoyl: a new lipophilic immunomodulator.
A new lipophilic immunomodulator, disaccharide tripeptide glycerol dipalmitoyl (DTP-GDP), has been synthesized and evaluated for its immunologic activity and toxicology. DTP-GDP alone or in liposomes is more effective as an adjuvant and in activating macrophages compared with muramyldipeptide (MDP). Preclinical studies demonstrate no evidence of toxicity, including vasculitis. DTP-GDP in liposomes has shown antitumor activity in phase I clinical trials.
ImmunoTherapeutics, Inc., Fargo, ND 58102.
G J
GJ
Vosika
D A
DA
Cornelius
J A
JA
Bennek
J R
JR
Sadlik
C W
CW
Gilbert
D000119:Acetylmuramyl-Alanyl-Isoglutamine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D000276:Adjuvants, Immunologic / Q000138:chemical synthesis / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D001685:Biological Factors / Q000378:metabolism; D016207:Cytokines; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D004187:Disaccharides / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D005334:Fever / Q000139:chemically induced; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008081:Liposomes; D008262:Macrophage Activation / Q000187:drug effects*; D051379:Mice; D008807:Mice, Inbred BALB C / Q000276:immunology; D010168:Palmitates / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D010169:Palmitic Acids / Q000494:pharmacology*; D011817:Rabbits; D012513:Sarcoma, Experimental / Q000628:therapy
D000276:Adjuvants, Immunologic; D001685:Biological Factors; D016207:Cytokines; D004187:Disaccharides; D008081:Liposomes; D010168:Palmitates; D010169:Palmitic Acids; C064104:N-acetylglucosamine-N-acetylmuramyl-alanyl-isoglutaminyl-alanyl-glycerol dipalmitoyl; D000119:Acetylmuramyl-Alanyl-Isoglutamine